|
Symposium
[Free Online Symposium] Advances in Cancer Therapeutics
Speakers:
Thorsten Melcher, RefleXion Medical; Erin Filbert, Apexigen; Pina Cardarelli, GPCR Therapeutics; Seema Kantak, Exelixis; Samuel Blackman, Day One Biopharmaceuticals; Holger Wesche, Harpoon Therapeutics Inc.; Mikayel Nazloyan, PricewaterhouseCoopers; James Trager, Nkarta Therapeutics; Kristin Bedard, Sutro Biopharma; Sarah Bodary, AbCellera; Steve Kelsey, Revolution Medicines; Tian Zhao, OncoNano
Organizers:
Snow Ge, PhD; Toby Freedman, PhD; Wenfeng Xu, PhD; Donald McCarthy, PhD; Betty Chang, PhD; Joe Carlino, PhD; Peter Staehr, MD; Shichang Miao, PhD
Date:
2022-08-17- 08/18/2022
Time:
8:30-12:30 Pacific Time
Registration fee:
0
Location:
Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2022-08-16
(it will close sooner if the seating cap is reached)
About the Topic
Note: This is an online meeting, The Zoom link will be sent to the registrants 1+ days before the event. About the Speakers
- James Trager, CSO, Nkarta Therapeutics
- Kristin Bedard, VP Discovery, Sutro Biopharma
- Pina Cardarelli, CSO, GPCR Therapeutics
- Seema Kantak, SVP, Head of Biologics & Biotherapeutics, Exelixis
- Samuel Blackman, CMO, Day One Biopharmaceuticals
- Erin Filbert, Director of IO, Apexigen
- Steve Kelsey, President, Research and Development, Revolution Medicines
- Thorsten Melcher, CBO, RefleXion Medical
- Mikayel Nazloyan, Partner, PricewaterhouseCoopers
- Sarah Bodary, VP Portfolio Innovation and Partnering, AbCellera
- Holger Wesche, CSO, Harpoon Therapeutics Inc.
- Tian Zhao, VP R&D, OncoNano
August 17th Agenda
|
Time (PDT)
|
Time (EST)
|
Topic
|
Presenter
|
|
8:30-8:45am
|
11:30-11:45am
|
Welcome Remarks
|
|
|
8:45-9:20am
|
11:45-12:20pm
|
Biology-Guided External-Beam Radiotherapy for All Stages of Cancer
|
Thorsten Melcher, PhD, CBO, RefleXion Medical
|
|
9:20-9:55am
|
12:20-12:55pm
|
APX601: a potent TNFR2 antagonist for reversing tumor-mediated immune suppression
|
Erin Filbert, PhD, Director of IO, Apexigen
|
|
9:55-10:30am
|
12:55-1:30pm
|
Targeting GPCRs: CXCR4 and ADRB2 for the Treatment of Cancer
|
Pina Cardarelli, PhD, CSO, GPCR Therapeutics
|
|
10:30-10:45am
|
1:30-1:45pm
|
Break
|
--
|
|
10:45-11:20am
|
1:44-2:20pm
|
Anti-tissue factor ADC. XB002: A novel anti-tissue factor ADC for the treatment of solid tumors
|
Seema Kantak, PhD, SVP, Head of Biologics & Biotherapeutics, Exelixis
|
|
11:20-11:55am
|
2:20-2:55pm
|
Clinical Development of Tovorafenib, a pan-RAF Inhibitor, for Relapsed/Progressive Pediatric Low-Grade Glioma
|
Sam Blackman, MD, PhD, CMO, Day One Biopharmaceutical
|
|
11:55-12:30pm
|
2:55-3:30pm
|
Novel Approaches to Expand the Therapeutic Index of T cell Engagers
|
Holger Wesche, PhD, CSO, Harpoon Therapeutics Inc.
|
|
12:30-12:50pm
|
3:30-3:50pm
|
PANEL DISCUSSION
|
All speakers
|
August 18th Agenda
|
Time (PDT)
|
Time (EST)
|
Topic
|
Presenter
|
|
8:30-8:45am
|
11:30-11:45am
|
Welcome Remarks
|
|
|
8:45-9:20am
|
11:45-12:20pm
|
Financing Trends in Oncology
|
Mikayel Nazloyan, Partner, PricewaterhouseCoopers
|
|
9:20-9:55am
|
12:20-12:55pm
|
Progress in the development of CAR NK cell therapies for cancer
|
James Trager, PhD, CSO, Nkarta, Inc
|
|
9:55-10:30am
|
12:55-1:30pm
|
Complex Biologics for Cancer Treatment: ADCs and Beyond
|
Kristin Bedard, PhD, VP Discovery, Sutro Biopharma
|
|
10:30-10:45am
|
1:30-1:45pm
|
Break
|
--
|
|
10:45-11:20am
|
1:44-2:20pm
|
Business Development trends in the dynamic oncology market
|
Sarah Bodary, PhD, VP Portfolio Innovation and Partnering, AbCellera
|
|
11:20-11:55am
|
2:20-2:55pm
|
Targeting RAS-addicted cancers with tricomplex RAS(ON) inhibitors
|
Steve Kelsey, MD, President, Research and Development, Revolution Medicines
|
|
11:55-12:30pm
|
2:55-3:30pm
|
Tumor specific delivery of therapeutics using a clinically validated ultra pH-sensitive nanoparticle platform
|
Tian Zhao, Ph.D., VP R&D, OncoNano Medicine
|
|
12:30-12:50pm
|
3:30-3:50pm
|
PANEL DISCUSSION
|
All speakers
|
2023-10-06, [In-Person] Human PK and Dose Prediction for Small Molecules
|
2023-11-07, [Free Online] The Science and Stories of Promising Biotech Startups
|
2023-11-13, [In-Person] Clinical Pharmacology Across the Drug Development Continuum: Key Clinical Studies, Modeling & Simulation to Support Drug Approval and Labeling
|
2023-12-06, [Free Online] Artificial Intelligence and Machine Learning to Drive Therapeutic Drug Discovery & Development
|
2024-01-19, [In-Person] ADME/DMPK Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
BioTether Sciences
Bioanalytical CRO, focused on PK, Biomarkers, and Immunogenicity. Custom Assay development, validation and testing. Advanced cell engineering.
|
Viva Biotech
Join Viva Reception if you have a need in MedChem, SBDD, FBDD, CryoEM, ASMS, SPR, HDX, CADD, Bioassay, CMC, Ab, https://www.bagevent.com/event/8673557
|
ICON
Innovation Workshop in SF Bay Area: Bringing the trial to the patient: Are you driving true patient centricity? Oct 19, Crowne Plaza Foster
|
Alturas Analytics, Inc.
Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
|
|
|
Submit a Text Ad
|